Developing guidelines for biotechnology drug use: experience with antithrombin III.
Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P & T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P & T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
Romac
D R
DR
UC Davis Medical Center, Sacramento, CA 95817, USA.
Poole
P
P
Owings
J T
JT
Mahackian
K
K
Foulke
G
G
Tharratt
R S
RS
Albertson
T E
TE
D000990:Antithrombin III / Q000627:therapeutic use*; D020152:Antithrombin III Deficiency; D001709:Biotechnology / Q000592:standards*; D002140:California; D002986:Clinical Trials as Topic; D003677:Deficiency Diseases / Q000188:drug therapy; D006785:Hospitals, University / Q000458:organization & administration / Q000592:standards*; D006801:Humans; D010595:Pharmacists; D010606:Pharmacy and Therapeutics Committee; D010820:Physicians; D017410:Practice Guidelines as Topic; D016730:Program Development